Cargando…
Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting
OBJECTIVES: Quick and inexpensive SARS-CoV-2 screening and frontline testing are in growing demand. Our study aimed to evaluate the performance of the immunochromatographic AMP rapid antigen test (AMP RAT) compared to the gold-standard real-time reverse transcription PCR (rRT-PCR) in a hospital coho...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168346/ https://www.ncbi.nlm.nih.gov/pubmed/34087486 http://dx.doi.org/10.1016/j.ijid.2021.05.063 |
_version_ | 1783701869560856576 |
---|---|
author | Leixner, Georg Voill-Glaninger, Astrid Bonner, Elisabeth Kreil, Anna Zadnikar, René Viveiros, André |
author_facet | Leixner, Georg Voill-Glaninger, Astrid Bonner, Elisabeth Kreil, Anna Zadnikar, René Viveiros, André |
author_sort | Leixner, Georg |
collection | PubMed |
description | OBJECTIVES: Quick and inexpensive SARS-CoV-2 screening and frontline testing are in growing demand. Our study aimed to evaluate the performance of the immunochromatographic AMP rapid antigen test (AMP RAT) compared to the gold-standard real-time reverse transcription PCR (rRT-PCR) in a hospital cohort. METHODS: A total of 392 patients, who presented consecutively with COVID-19 symptoms in our emergency department, were included in this retrospective study. Two swabs were collected per patient: a nasopharyngeal for the RAT and a combined naso- and oropharyngeal for the rRT-PCR. A positive rRT-PCR (defined as cycle threshold (Ct) < 40) was found in 94 (24%) patients. RESULTS: In our cohort with a median patient age of 70, overall sensitivity and specificity of the AMP RAT was 69.2% (58.8–78.3, 95% CI) and 99.7% (98.1–100.0, 95% CI), respectively. In patients with a Ct value < 25 and < 30, higher sensitivities of 100.0% (89.4–100.0, 95% CI) and 91.8% (81.9–97.3%, 95% CI) were observed. CONCLUSIONS: The AMP RAT showed a high sensitivity in patients with a Ct value < 25 and < 30 and might be helpful for frontline testing whenever rRT-PCR is not readily available. |
format | Online Article Text |
id | pubmed-8168346 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81683462021-06-01 Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting Leixner, Georg Voill-Glaninger, Astrid Bonner, Elisabeth Kreil, Anna Zadnikar, René Viveiros, André Int J Infect Dis Article OBJECTIVES: Quick and inexpensive SARS-CoV-2 screening and frontline testing are in growing demand. Our study aimed to evaluate the performance of the immunochromatographic AMP rapid antigen test (AMP RAT) compared to the gold-standard real-time reverse transcription PCR (rRT-PCR) in a hospital cohort. METHODS: A total of 392 patients, who presented consecutively with COVID-19 symptoms in our emergency department, were included in this retrospective study. Two swabs were collected per patient: a nasopharyngeal for the RAT and a combined naso- and oropharyngeal for the rRT-PCR. A positive rRT-PCR (defined as cycle threshold (Ct) < 40) was found in 94 (24%) patients. RESULTS: In our cohort with a median patient age of 70, overall sensitivity and specificity of the AMP RAT was 69.2% (58.8–78.3, 95% CI) and 99.7% (98.1–100.0, 95% CI), respectively. In patients with a Ct value < 25 and < 30, higher sensitivities of 100.0% (89.4–100.0, 95% CI) and 91.8% (81.9–97.3%, 95% CI) were observed. CONCLUSIONS: The AMP RAT showed a high sensitivity in patients with a Ct value < 25 and < 30 and might be helpful for frontline testing whenever rRT-PCR is not readily available. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-07 2021-06-01 /pmc/articles/PMC8168346/ /pubmed/34087486 http://dx.doi.org/10.1016/j.ijid.2021.05.063 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Leixner, Georg Voill-Glaninger, Astrid Bonner, Elisabeth Kreil, Anna Zadnikar, René Viveiros, André Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting |
title | Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting |
title_full | Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting |
title_fullStr | Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting |
title_full_unstemmed | Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting |
title_short | Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting |
title_sort | evaluation of the amp sars-cov-2 rapid antigen test in a hospital setting |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168346/ https://www.ncbi.nlm.nih.gov/pubmed/34087486 http://dx.doi.org/10.1016/j.ijid.2021.05.063 |
work_keys_str_mv | AT leixnergeorg evaluationoftheampsarscov2rapidantigentestinahospitalsetting AT voillglaningerastrid evaluationoftheampsarscov2rapidantigentestinahospitalsetting AT bonnerelisabeth evaluationoftheampsarscov2rapidantigentestinahospitalsetting AT kreilanna evaluationoftheampsarscov2rapidantigentestinahospitalsetting AT zadnikarrene evaluationoftheampsarscov2rapidantigentestinahospitalsetting AT viveirosandre evaluationoftheampsarscov2rapidantigentestinahospitalsetting |